참고문헌
- Bacci G, Ferrari S, Lari S, et al (2002). Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br, 84, 88-92. https://doi.org/10.1302/0301-620X.84B1.12211
- Bagatell R, Norris R, Ingle AM, et al (2014). Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer, 61, 833-9. https://doi.org/10.1002/pbc.24874
- Bielack SS, Kempf-Bielack B, Delling G, et al (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 20, 776-90. https://doi.org/10.1200/JCO.20.3.776
- Bond M, Bernstein ML, Pappo A, et al (2008). A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer, 50, 254-8. https://doi.org/10.1002/pbc.21132
- Brennan RC, Furman W, Mao S, et al (2014). Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol, 74, 1191-8. https://doi.org/10.1007/s00280-014-2593-7
- Cartei G, Clocchiatti L, Sacco C, et al (2003). Dose finding of ifosfamide administered with a chronic two-week continuous infusion. Oncology, 65, 31-6. https://doi.org/10.1159/000073355
- Choeyprasert W, Pakakasama S, Sirachainan N, et al (2014). Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. Asian Pac J Cancer Prev, 15, 9823-9. https://doi.org/10.7314/APJCP.2014.15.22.9823
- Chuk MK, Aikin A, Whitcomb T, et al (2012). A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis (R), ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatr Blood Cancer, 59, 865-9. https://doi.org/10.1002/pbc.24201
- Crews KR, Stewart CF, Liu T, et al (2004). Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol, 26, 764-7. https://doi.org/10.1097/00043426-200411000-00016
- De Pas T, Rosati G, Spitaleri G, et al (2011). Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. Chemotherapy, 57, 217-24. https://doi.org/10.1159/000326466
- Ferrari S, Briccoli A, Mercuri M, et al (2003). Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol, 21, 710-5. https://doi.org/10.1200/JCO.2003.03.141
- Harris MB, Cantor AB, Goorin AM, et al (1995). Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol, 24, 87-92. https://doi.org/10.1002/mpo.2950240205
- Hawkins DSand Arndt CA (2003). Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer, 98, 2447-56. https://doi.org/10.1002/cncr.11799
- Kobys VL, Konovalenko VF, Repinsmall a CNV, et al (2013). Treatment of large osteosarcoma in children: new approach. Exp Oncol, 35, 105-8.
- Kudawara I, Aoki Y, Ueda T, et al (2013). Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan. J Chemother, 25, 41-8. https://doi.org/10.1179/1973947812Y.0000000055
- Li YY, Jiang XM, Dong YG, Xu G, Ma YB (2014). Ifosfamide-containing regimens for treating patients with osteosarcomas. Asian Pac J Cancer Prev, 15, 9763-6. https://doi.org/10.7314/APJCP.2014.15.22.9763
- Meyers PA, Schwartz CL, Krailo M, et al (2005). Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 23, 2004-11. https://doi.org/10.1200/JCO.2005.06.031
- Palumbo R, Palmeri S, Antimi M, et al (1997). Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Ann Oncol, 8, 1159-62. https://doi.org/10.1023/A:1008279426654
- Qi WX, He AN, Tang LN, et al (2012). Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Jpn J Clin Oncol, 42, 427-31. https://doi.org/10.1093/jjco/hys030
- Qi WX, He AN, Tang LN, et al (2012). Evaluation of pirarubicin-cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute. Med Oncol, 29, 2229-33. https://doi.org/10.1007/s12032-011-0021-y
- Saeter G, Hoie J, Stenwig AE, et al (1995). Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer, 75, 1084-93. https://doi.org/10.1002/1097-0142(19950301)75:5<1084::AID-CNCR2820750506>3.0.CO;2-F
- Seibel NL, Krailo M, Chen Z, et al (2007). Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: children's Cancer Group (CCG) 7943. Cancer, 109, 1646-53. https://doi.org/10.1002/cncr.22553
- Singer JM, Hartley JM, Brennan C, et al (1998). The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. Br J Cancer, 77, 978-84. https://doi.org/10.1038/bjc.1998.161
- Sluga M, Windhager R, Lang S, et al (1999). Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res, 120-7.
- Ta HT, Dass CR, Choong PF, et al (2009). Osteosarcoma treatment: state of the art. Cancer Metastasis Rev, 28, 247-63. https://doi.org/10.1007/s10555-009-9186-7
- Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors. european organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205-16. https://doi.org/10.1093/jnci/92.3.205
- Wilkins RM, Cullen JW, Odom L, et al (2003). Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol, 10, 498-507. https://doi.org/10.1245/ASO.2003.03.061
피인용 문헌
- Association of Metastasis with Clinicopathological Data in Mexican Patients with Osteosarcoma, Giant Cell Tumor of Bone and Chondrosarcoma vol.16, pp.17, 2015, https://doi.org/10.7314/APJCP.2015.16.17.7689